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Abstract
Background: Crohn’s disease (CD) is a chronic granulomatous inflammation of the intestine. The etiology is unknown, but
an excessive immune response to bacteria in genetically susceptible individuals is probably involved. The response is
characterized by a strong Th1/Th17 response, but the relative importance of the various bacteria is not known.
Methodology/Principal Findings: In an attempt to address this issue, we made T-cell lines from intestinal biopsies of
patients with CD (n = 11), ulcerative colitis (UC) (n = 13) and controls (n = 10). The T-cell lines were tested for responses to
various bacteria. A majority of the CD patients with active disease had a dominant response to Mycobacterium avium
subspecies paratuberculosis (MAP). The T cells from CD patients also showed higher proliferation in response to MAP
compared to UC patients (p,0.025). MAP reactive CD4 T-cell clones (n = 28) were isolated from four CD patients. The T-cell
clones produced IL-17 and/or IFN-c, while minimal amounts of IL-4 were detected. To further characterize the specificity, the
responses to antigen preparations from different mycobacterial species were tested. One T-cell clone responded only to
MAP and the very closely related M. avium subspecies avium (MAA) while another responded to MAP, MAA and
Mycobacterium intracellulare. A more broadly reactive T-cell clone reacted to MAP1508 which belongs to the esx protein
family.
Conclusions/Significance: The presence of MAP reactive T cells with a Th1 or Th1/Th17 phenotype may suggest a possible
role of mycobacteria in the inflammation seen in CD. The isolation of intestinal T cells followed by characterization of their
specificity is a valuable tool to study the relative importance of different bacteria in CD.
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Introduction
Crohn’s disease (CD) is an intestinal disorder characterized by
granulomatous inflammation. The etiology is still unknown, but it
is generally believed that an inappropriate inflammatory response
to the commensal bacteria is involved [1]. Lately it has become
clear that the risk of developing CD is associated with
polymorphisms in several genes that are involved in interaction
with bacteria. In particular, NOD2 [2,3], which is an intracellular
sensor of bacteria, and ATG16L1 [4] and IRGM [5], which are
involved in autophagy, are genetic factors for CD. NOD2 activates
an NF-kB signaling pathway upon binding of the bacterial
peptidoglycan component muramyl dipeptide (MDP), but exactly
how NOD2 is involved in CD has not been settled. There is
evidence both for loss and gain of functions [6,7]. Autophagy, with
involvement of ATG16L1 and IRGM, is an important constitutive
cellular process involved in protein turnover and the removal of
subcellular components. Recently ATG16L1 was shown to be
important for the biology of intestinal Paneth cells [8], and
interestingly the autophagy pathway is also important for
resistance against intracellular bacteria [9]. Functional knock
down of ATG16L1 abrogated autophagy of the intracellular
pathogen Salmonella typhimurium [10]. Moreover, knockdown of
IRGM leads to markedly prolonged survival of Mycobacterium
tuberculosis in human macrophages [11]. It is notable that NOD2,
ATG16L1 and IRGM are all risk factors for CD but not ulcerative
colitis (UC), while many other genes including the IL-23 r gene and
the IL-12B gene [12] , coding for the common p40 subunit of IL-12
and IL-23, are susceptibility determinates for both conditions. This
indicates that some of the inflammatory pathways are likely shared
between the two conditions, while the importance of immune
handling of bacteria differentiates CD pathophysiology from UC.
At this stage it is unclear whether the CD associated variants of
NOD2, ATG16L1 and IRGM influence the host response to
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particular bacteria or whether they have more general effects to a
wide range of gut bacteria. Several bacteria have been suggested to
be involved in CD pathogenesis including Escherichia coli and
Mycobacterium avium subspecies paratuberculosis (MAP). Invasive E.
coli have been found in higher frequencies in ileal CD [13]. The
data on the presence of MAP are not uniform, but two meta-analysis
of several published studies have concluded that MAP is more often
present in CD patients than patients with UC and non-inflammatory
bowl disease (non-IBD) [14,15]. However whether the bacterium
can contribute to the inflammatory response is not known.
The CD lesions are transmural, and typically they have
granulomas and lymphoid aggregates with abundance of CD4+ T
cells that produce inflammatory cytokines like IL-17 and IFN-c [16].
To get more information about the bacteria involved in CD
pathogenesis one approach is to isolate intestinal T cells. Studies of
the specificity of intestinal T-cells in CD are limited. A decade ago
Duchman et al showed that both CD and ulcerative colitis (UC)
patients had T cells with reactivity to various commensal bacteria,
including E. coli, however no differences were found between the two
groups [17,18]. To get information about the relative importance of
various bacteria in the ability to elicit an inflammatory T cell
response, we chose to characterize the specificity of intestinal T cells
from CD patients. We subsequently isolated T cells from intestinal
biopsies of CD, UC and non-IBD patients and detected responses to
all the tested bacteria. However, CD patients had a higher frequency
of MAP reactive T cells than the UC patients and also a higher
frequency of response to MAP compared to other bacterial antigens.
Furthermore these T cells produced inflammatory cytokines like
IFN-c and IL-17. Our data justify further studies into the possible
role of mycobacteria in CD immunopathology.
Methods
Study subjects
Intestinal biopsies were obtained by colonoscopy from adult
patients with CD (n = 11), UC (n = 13) and non-IBD (n = 10). The
colonoscopy was performed as a part of the routine investigation.
Patients with endoscopically active and inactive disease were
included. Patients that had received, or were receiving anti-TNF-a
treatment, were not included. Of the CD patients (2 men, 9
women), four had inactive while seven had active disease. The
average age was 45 years (range 27–66) and the average time since
diagnosis was 19 years (range 5–28). Of the UC patients (8 men, 5
women), five had inactive disease while eight had active disease.
The average age was 41 years (range 19–61) and the average time
since diagnosis was 12 years (range 2–30). The average age of non-
IBD patients (3 men, 7 women) was 49 years (range 18–73).
Information about disease localization, medication and diagnosis is
given in table 1. All patients gave written informed consent before
the colonoscopy. The study was approved by the Regional
Committee for Medical Research Ethics, South Norway, and
approval for storing of biological materials was obtained by the
Norwegian Directorate for Health and Social Affairs.
HLA-typing
The patients were genomically HLA typed using the Olerup
SSP HLA kits for DQB1*, DRB1*, DPB1* (GenoVision/Qiagen)
or serologically typed by a complement dependent cytotoxicity test
with immunomagnetically separated cells (DynabeadsH HLA class
II, Invitrogen).
Strains and antigens
The following strains were used to prepare the antigens:
Bacterioides thetaiotaomicron CCUG 12297, Lactobacillus gasseri CCUG
39972, Bifidobacterium bifidum CCUG 45217, Escherichia coli ATCC
43893 (enteroinvasive), M. avium subsp. paratuberculosis 2E,
Mycobacterium avium subspecies avium D4, Mycobacterium intracellulare
MNC72, Mycobacterium gordonae MNC 64, Mycobacterium tuberculosis
clinical isolate. The bacteria were grown on standard medium
under recommended conditions. The cells were scraped off the
agar plates, sonicated (two cycles of 10 min) and centrifuged. The
supernatants were sterile filtered (0.2 mm) before the protein
concentration was assessed according to Lowry [19] using the Bio-
Rad DC Protein Assay (Bio-Rad Laboratories, Hercules, CA,
USA). The mycobacterial antigens were prepared as previously
described [20]. In short, mycobacteria were grown as a surface
pellicle on liquid Reids or Sauton medium. Proteins secreted by
the bacteria into the culture medium were precipitated using
ammonium sulphate, dissolved in PBS, dialysed and sterile
filtrated (0.2 mm). Recombinant MAP antigens and pooled
peptides from single MAP antigens used for testing are listed in
Table S1. Synthetic peptides were purchased from Genscript, NJ,
USA.
Antibodies
The following antibodies were used for analyzing T cells by flow
cytometry: anti-TCR ab FITC (IgM, clone T10B9.1A-31), anti-
CCR6 PE (IgG1k, clone 11A9), anti-TCRcd APC (IgG1k, clone
B1), anti- IFNc FITC (IgG1k, clone 4S.B3) isotype control FITC
(IgM, clone G155-228) isotype control PE (IgG1k, clone MOPC-
21) (all BD Pharmingen); anti-CD4 PE (IgG2a, clone EDU-2),
anti-CD8 FITC (IgG2a, clone UCHT-4), Isotype PE (IgG2A,
clone BH1), Isotype FITC (IgG2A, clone BH1) (all Diatec) and
anti-IL-17a Alexa fluor647 (IgG1k, clone eBio64DEC17)
(ebioscience). Anti-CD56 (IgG2a, clone MEM 188) and goat
anti-mouse-IgG2a FITC (Southern Biotechnology).
The HLA restriction of the T cells was determined by testing
inhibition of T-cell proliferation in the presence of monoclonal
antibodies B8.11 (pan-DR), SPV-L3 (pan-DQ) or B7/21 (pan-DP)
at a concentration of 20 mg/ml.
Establishment of T-cell lines and clones
The protocol for establishment of T-cell lines was adapted from
the protocol used for establishing T-cell lines from small intestinal
biopsies of celiac disease patients [21,22] with some modifications.
The biopsies were taken from the distal part of the small intestine,
or upper part of colon. In patients with active disease, biopsies
were taken from inflamed mucosa and from the surrounding non-
inflamed areas. Separate, single biopsy specimens from each
location were incubated with either complete medium (RPMI
1640 (Gibco) containing 10% human serum, b mercaptoethanol,
penicillin, streptomycin and fungizone) or complete medium with
MAP (100 mg/ml) overnight. After incubation the biopsies were
homogenized for 120 seconds in a BD Medimachine Medicon
(BD MedimachineTM Medicon, 35 mm Sterile). The single cells
from each biopsy were centrifuged, dissolved in 1 ml complete
medium containing 26106 autologous, irradiated (25 Gy) PBMC,
10 U/mL human IL-2 (R&D Systems, Abingdon, UK), and 1 ng/
mL human IL-15 (R&D Systems) and seeded into 8 wells on a U-
bottomed 96-well plate. On day 8, cells from duplicate wells were
restimulated separately with 16106 allogenic, irradiated PBMC,
10 U/mL IL-2, 1 ng/mL IL-15, and 1 mg/mL phytohemagglu-
tinin (Remel) in a 48-well plate and propagated as four separate T-
cell lines. The four lines established from each biopsy were tested
in triplicates on day 15.
T-cell clones were generated from MAP and E. coli reactive
biopsy-derived T-cell lines. The T cells were diluted in irradiated
feeders from three donors with IL-2, IL-15 and PHA as described
CD4 T Cells in Crohn’s Disease
PLoS ONE | www.plosone.org 2 May 2009 | Volume 4 | Issue 5 | e5641
above and seeded on Terasaki plates (Greiner Bio-One) at a
concentration of 0.3–3 cells/well. After 9 days, growing T-cell
clones were transferred to 48 well plates and restimulated as
before. Established T-cell clones were tested for reactivity to MAP
or E. coli. T-cell clonality was tested by the IOTestH Beta Mark
(Beckman Coulter) TCR Vb staining kit covering about 70% of
the normal human TCR Vb repertoire of CD3+ lymphocytes.
APC and T cell proliferation assay
Testing of the reactivity of the T-cell lines was done by assessing
proliferation in restimulation assays using irradiated adherent cells
as APC. The APC were isolated by incubating PBMC (50 000
cells/well, 96 well plate) in medium containing 15% FCS for
1.5 hours. The wells were washed three times in medium with
15% FCS before medium with 10% human serum and antigens
were added. The plates were irradiated (25 Gy) the next day
before the T cells were added. Autologus adherent cells from
frozen PBMC were used for all initial screenings while HLA-II
matched donors or autologus APC were used for later testing. The
cells were incubated for three days with the addition of 3H
thymidine for the last 20 hours. Proliferation was assessed by
scintillation counting after harvesting of the cultures. Positive T-
cell responses were defined as a stimulatory index (SI) above 5
([T+APC+antigen] divided by [T+APC]).
The following homozygous B-lymphoblastoid cell lines derived
from the 10th and 11th International Histocompatibility Workshop
Table 1. Patient characteristics
CD Disease localisation and actvity Medication
CD-6 Small intestine (inactive) Azathioprin
CD-9 Small intestine and colon (active) Topical steroids
CD-10 Colon (active) Prednisolone
CD-11 Small intestine (inactive) None
CD-15 Colon, fistulas (active) None
CD-18 Small intestine and colon (active) Mesalazine, Budesonide CR, Colestyramine
CD-33 Colon (inactive) Azathioprin
CD-36 Colon (inactive) None
CD-46 Ileocecal and perianal (active) None
CD-47 Small intestine, ileocecal and perianal (active) Azathioprin
CD-48 Colon (active) Balsalazide, Prednisolone
UC Disease localisation and actvity Medication
UC-14 Pancolitis (active) Azathioprin, Balsalazide, Budesonide CR
UC-16 Proctitis (active) Mesalazine topical
UC-17 Pancolitis (inactive) Mesalazine, Prednisolone, Tacrolimus
UC-19 Pancolitis (inactive) Mesalazine
UC-25 Proctitis (inactive) None
UC-27 Pancolitis (active) Prednisolone
UC-31 Pancolitis (active) None
UC-32 Pancolitis (active) Balsalazide
UC-35 Pancolitis, inactive) Balsalazide
UC-37 Pancolitis (inactive) None
UC-40 Pancolitis (active) Mesalazine
UC-44 Proctitis (active) Mesalazine topical
UC-45 Pancolitis (active) Mesalazine
non IBD Diagnosis Medication
non IBD-20 Diarrhea None
non IBD-23 Healthy, family history of colon cancer None
non IBD-24 Cancer control Levotyroksin, allergy medication
non IBD-26 Familial adenomatous polyposis None
non IBD-28 Healthy, family history of colon cancer None
non IBD-30 Cancer control None
non IBD-34 Healthy, family history of colon cancer None
non IBD-13 Primary sclerosing cholangitis, no sign of UC or CD None
non IBD-49 Healthy, family history of colon cancer None
non IBD-51 Celiac disease None
doi:10.1371/journal.pone.0005641.t001
CD4 T Cells in Crohn’s Disease
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(IHWS) were used as APC for identification of HLA restriction of
the MAP1508 specific T-cell clone: #9002/MZ070782;
(DRB1*0102, DQA1*0101, DQB1*0501, DPB1*0401), #9003/
KAS116; (DRB1*0101, DQA1*0101, DQB1*0501, DPB1*1301),
#9042/TISI; (DRB1*1103, DQA1*0501, DQB1*0301,
DPB1*0402), #9055/H0301; (DRB1*1302, DQA1*0102,
DQB1*0605, DPB1*0501), #9063/WT47; (DRB1*1302,
DQA1*0102, DQB1*0604, DPB1*1601) and YT (DRB1*0405,
DQA1*03, DQB1*0401, DPB1*0501). The B-cell lines were all
irradiated with 75 Gy before use.
Staining of intracellular cytokines
T-cell clones (approximately 500 000 cells) were stimulated with
PMA (10 ng/ml) and ionomycin (2 mM) or left unstimulated.
Monensin was added and the cells were incubated for 18 hours
followed by staining for intracellular IFN-c and IL-17. Briefly the
cells were fixed in 1% PFA for one hour and permabilized in PBS
with 2% FCS and 0.2% saponin for 30 minutes. The cells were
stained with antibodies against IFN-c and IL-17a and analyzed on
a FACS CALIBUR flow cytometer (Becton Dickinson), equipped
with Cell-Quest software.
Cytokine assays
The amount of cytokines was measured in supernatant from
antigen stimulated T-cell clones and unstimulated controls. The
stimulation was performed as for the T-cell proliferation assay, and
the supernatant was removed after 48 hours and stored at 220C
until tested. As a control for T-cell viability 3H thymidine was
added and the T-cell proliferation measured after incubation for
another 24 hours. The amount of cytokines was measured using
the Bio-plexTM Cytokine Assay, (Bio-Rad) according to the
manufacturer’s instructions. Values above the detection limits
defined by the standard curve were considered positive.
Statistics
The Wilcoxon Mann-Whitney non-parametric test was used to
compare patient groups and p,0.05 was considered significant.
Results
Reactivity of intestinal T cells to various bacterial antigens
The T-cell lines generated without ex vivo stimulation with any
antigen, were tested for responses in a T-cell proliferation assay
against antigen preparations from B. thetaiotaomicron, L. gasseri, B.
bifidum, E. coli and MAP. Minimal responses were seen in patients
with inactive disease and in non-IBD patients while the results
from CD patients with active disease are summarized in Table 2.
T-cell lines that reacted to MAP were detected in 5 of 7 (71%)
patients in the CD group. Next to MAP, responses to E. coli were
most frequently detected, and one CD patient (CD-47) had a
strong response to E. coli with no response to MAP. More T-cell
lines reacted to MAP than to the other bacterial antigens in the
CD group, while in the UC group there were similar responses to
MAP and the commensal bacteria (Table 3). Some of the T-cell
lines, especially in the CD group, exhibited extensive multi-
reactivity with response to several of the tested antigen
preparation. Whether the multi-reactivity was due to cross reactive
T cells or the presence of multiple specificities in the T-cell lines
was not investigated. There were no systematic differences
between T-cell lines obtained from biopsies from inflamed area
and biopsies taken from the surrounding non-inflamed area.
Next we wanted to enrich for mycobacteria reactive T cells, and
lines were therefore also generated from intestinal biopsies
stimulated with MAP ex vivo. These lines were tested for response
to MAP. The MAP stimulated biopsies from non-inflamed mucosa
of one CD patient and one UC patient with active disease were
contaminated and disregarded. The mean response in T-cell lines
generated from non-inflamed mucosa of CD patients was
significantly (p,0.025) higher than the responses in UC patients
(Figure 1A). A similar tendency was seen in T cells from inflamed
mucosa (not statistically significant, data not shown). The
responses were strongest in CD patients with active disease
compared to CD patients with inactive disease (p,0.05)
(Figure 1B). Proliferation was however also detected in T-cell
lines from some of the patients with inactive CD and in some
control patients. These patients usually had responses in one single
line T-cell line while patients with active CD had responses in
several T-cell lines suggesting a higher frequency of MAP reactive
T cells in the latter group. The three CD patients (CD-10, CD-33
and CD-36) with no detectable response to MAP in any of the
tested T-cell lines had colon involvement only (Table 1).
Cytokine response in MAP and E. coli responsive T-cell
clones
In addition to MAP, E. coli was the bacterial antigen eliciting the
strongest responses in CD patients.To further characterize the T
Table 2. Response to various bacteria in T-cell lines from CD patients with active disease.
Number of positiveA T-cell lines (n = 8)
MAP B. thetaiotaomicron B. bifidum L. gasseri E. coli
CD-9 5 (2)B 1 (1) 2 (2) 2 (2) 1 (1)
CD-18 5 (2) 1 (1) 0 0 2 (2)
CD-15 7 (0) 0 0 0 0
CD-48 2 (0) 0 1 (1) 1 (1) 0
CD-46 2 (2) 1 (1) 1 (1) NDC 3 (2)
CD-47 0 1 (1) 0 0 3 (1)
CD-10 0 0 0 0 0
APositive lines are defined as SI.5
BSome lines reacted to several bacterial antigens. The total number of positive lines to each bacterium is shown. The number in brackets shows how many of these lines
that were multi-reactive.
CND = not done
doi:10.1371/journal.pone.0005641.t002
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cells in CD patients, we attempted to isolated single T-cell clones
from three patients with strong MAP responses, one patient with a
strong E. coli response and one patient with a mixed MAP and E.
coli response. Altogether we obtained 28 T-cell clones (CD-46:17
clones, CD-11: 3 clones, CD-6: 2 clones and CD-9: 6 clones) that
reacted to MAP antigens. From patient CD-46, who had a mixed
response we also obtained eight E. coli reactive T-cell clones. From
patient CD-47 with a strong E. coli response, a loss of reactivity was
seen after expansion of the T-cell line and cloning was thus
abandoned.
CD patients have a granulomatous inflammation with excessive
production of IL-17 and IFN-c in the intestine [16]. We thus
wanted to see whether the MAP reactive and the E. coli reactive T-
cell clones secreted any of these inflammatory cytokines. Two
MAP reactive T-cell clones could not be expanded and thus
excluded from further studies. The T-cell clones were incubated
with MAP (n = 26) or E. coli (n = 8) antigens using HLA-II matched
adherent cells as APCs and the supernatant was assayed for IFN-c,
IL-17 and IL-4. All the MAP reactive clones produced IFN-c
(ranging from 88 to 9786 pg/ml) and 23 of 26 clones produced IL-
17 (ranging from 25 to 4320 pg/ml), while low levels of IL-4
(,17 pg/ml) was detected in three clones. The E. coli reactive
clones produced some IL-17 (411 pg/ml681) and lower, but
detectable amounts of IFN-c (117 pg/ml625). In comparison the
MAP reactive clones (n = 17) from the same patient produced a
mean of 1593 pg/ml6328 of IL-17 and 1770 pg/ml6631 of IFN-
c (Figure 2A). Although most of the MAP reactive clones produced
both IFN-c and IL-17 they appeared to have either a dominant
IL-17 secretion or a dominant IFN-c production (Figure 2B). To
see if polyclonal activation would give a different cytokine pattern,
three clones producing only IFN-c and two clones producing
predominantly IL-17 but with detectable IFN-c in response to
MAP, were stimulated with PMA/ionomycin. The results were
comparable to what was seen after antigen stimulation of the same
clones. No IL-17 was detected in the IFN-c secreting clones while
the IL-17 producing clones made both cytokines (Figure 2C). This
suggested that MAP reactive clones with a Th1 and a Th1/Th17
mixed phenotype were present in CD patients. A typical marker of
IL-17 producing cells is the chemokine receptor CCR6, and all but
one T-cell clone expressed CCR6 (Figure 2D). The CCR6
negative clone, TCC906A.8.4.15, had a Th1 phenotype with no
detectable IL-17 in response to MAP or PMA/ionomycin.
Figure 1. T-cell responses to MAP. Autologous adherent cells were incubated with antigen overnight and T cells were added followed by
incubation for three days. 3H thymidine was added for the last 20 hours, and proliferation was assessed by scintillation counting after harvesting of
the cultures. A) Depiction of results from all patients. B) Depiction of the same results, but where the material is divided into subgroups with active
and inactive disease; active CD; n = 6, inactive CD; n = 4, active UC; n = 7, inactive UC; n = 5. Each symbol represents the mean response in four T-cell
lines made from one patient. The lines were screened in triplicates and the results are given as CPM [ (T+ APC + MAP)2(T+APC)]. There was a
significant difference between CD and UC patients (p,0.025) and between patients with active and inactive CD (p,0.05) using the non-parametric
Wilcoxon Mann-Whitney test. Error bars indicate the mean response in the group6SEM.
doi:10.1371/journal.pone.0005641.g001
Table 3. Reactivity of T-cell lines to MAP and commensal
bacteria in CD and UC patients with active disease
Number of positiveA T-cell lines (n = 8)
MAPB Multi-reactive C CommensalD
CD patients
CD-9 3 2 0
CD-18 3 2 0
CD-15 7 0 0
CD-48 2 0 1
CD-46 0 2 1
CD-47 0 0 3
CD-10 0 0 0
UC patients
UC-27 4 0 0
UC-40 1 0 0
UC-14 0 0 0
UC-31 0 1 3
UC-32 0 0 1
UC-45 0 0 1
UC-44 0 0 0
UC-16 0 0 0
APositive lines are defined as SI.5
BLines reacted only with MAP.
CLines reactive with MAP and one or more commensal bacteria
DLines reactive to one or more of the following commensal bacteria: B.
thetaiotaomicron, L. gasseri, B. bifidum, E. coli
doi:10.1371/journal.pone.0005641.t003
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MAP reactive T-cell clones from CD patients showed a
dominant response to the M. avium-intracellulare
complex
MAP share several highly cross-reactive antigens with other
mycobacteria, and exposure to environmental mycobacteria could
lead to detectable T-cell responses. The T-cell clones were
subsequently screened for reactivity to various crude antigen
preparations from different mycobacterial species. Most of the T-
cell clones showed some degree of cross-reactivity, however one
clone (TCC946.A.8.2b.5 from CD-46) responded only to MAP
and the very closely related Mycobacterium avium subspecies avium
Figure 2. Cytokine responses in T-cell clones. A) Comparison of cytokine response in MAP reactive (n = 17) and E. coli reactive (n = 8) T-cell
clones from the same CD patient (CD-46). T-cell clones were stimulated with MAP or E. coli antigens (10 mg/ml) for 48 hours using HLA class II
matched irradiated adherent cells as APC. Supernatants from duplicate wells were sampled and tested for cytokine production. Cytokine production
in control wells was subtracted. One symbol represents one clone. Error bars indicate mean6SEM. B) IL-17 and IFN-c production in MAP reactive T-
cell clones (n = 26) from four different CD patients in response to MAP antigen. C) Intracellular staining of IFN-c and IL-17 after stimulation with PMA/
ionomycin in a Th1 (TCC906.A.8.4.15) clone and a Th1/Th17 clone (TCC946.A.8.2b.17). Filled histogram represent PMA/ionomycin samples and open
histograms represent unstimulated samples. D) CCR6 expression in a Th1 clone and (top) and a Th1/Th17 clone (bottom). Filled histograms represent
CCR6 expression and open histograms represent isotype control.
doi:10.1371/journal.pone.0005641.g002
CD4 T Cells in Crohn’s Disease
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MAA (Figure 3). Another clone (TCC909A.8.2.7) from a different
patient (CD-9) responded to MAP, MAA and had a low, but
detectable response to Mycobacterium intracellulare. The percentages
of MAP reactive T-cell clones responding to the other mycobac-
teria were, MAA 100%, M. intracellulare 92%, M. gordonae 65% and
M. tuberculosis 31%.
HLA restriction
The T-cell restriction was determined using APCs from DR/
DQ haplotype matched donors together with blocking of the
response in a T-cell assay by adding specific anti-HLA-DP, anti-
HLA-DQ and anti-HLA-DR antibodies (Figure 4). The MAP
reactive clones from two of the patients (CD-6 and CD-9) were
DR restricted (n = 7) while DQ restricted clones (n = 18) were
obtained from the two others (CD-11 and CD-46). The
response could be blocked in all clones except three. These
clones were CD4+, TCRab+, CD56- and appeared to be
conventional T cells. One could speculate that they might
recognize antigen in the context of CD1 which is seen in other
mycobacterial infections. However, this was not pursued in the
present study.
Characterization of a T-cell clone responding to MAP1508
Finally we aimed to identify which antigen in the crude MAP
preparation the T cells responded to. T-cell lines and a selection of
T-cell clones were thus tested for responses against a range of
available recombinant purified MAP antigens or pools of
overlapping peptides (Table S1). One T-cell line had a strong
response to pooled peptides from MAP1508 [23] which is 87%
identical to esxP from M. tuberculosis. By cloning of this line we
isolated a T-cell clone (TCC911.A.8.4.13) responding to this
antigen. The T-cell clone recognized the peptides in the context of
HLA-DQ as showed by adding anti-HLA-DP, anti-HLA-DQ or
anti-HLA-DR antibodies (Figure 5A). The patient was
DQB1*0609 and DQB1*0301. HLA-DQ matched EBV cells
were used as APC, and the results indicated that this clone
recognized the peptide in the context of DQ6 (i.e. DQA1*0102/
DQB1*0605). The clone did not recognize the peptide in the
context of DQA1*0102/DQB1*0604, which might be due to a
histidine at position 30 in DQB1*0604 compared to a tyrosine in
DQB1*0605 and DQB1*0609. Epitope mapping demonstrated
that the epitope was located at aa position 71-80 of MAP1508
(Figure 5B). Protein Blast using these 10 aa confirmed that the
epitope is conserved in several of the pathogenic mycobacteria
including the M. avium complex and the M. tuberculosis complex,
while it was not found in the non-pathogenic Mycobacterium
smegmatis mc2 155. Staining for TCR Vb showed that the clone
expressed the TCR Vb8 chain. Furthermore, the clone was
CD4+, Tab+ CCR6+, and it produced IFN-c and not IL-17 in
response to PMA/ionomycin (data not shown). The T cells from
the other patients did not recognize any of the available purified
antigens.
Discussion
This study demonstrated that T cells reacting to various bacteria
were present in the intestine of patients with CD, however a
majority of the patients had a dominant response to MAP. The T
cells secreted IFN-c and IL-17, and a role for mycobacteria in the
excessive inflammation seen in CD cannot be excluded. The
isolation of T cells together with identification of their specificity is
a useful approach to get answers about the relative importance of
various bacteria in CD.
Although the CD lesions have increased number of CD4 T cells
producing inflammatory cytokines, very few studies have focused
Figure 3. Responses of T-cell clones to various mycobacteria. Proliferation of T-cell clones from two different CD patients (CD-9 and CD-46)
after stimulation with crude antigen preparations from various mycobacteria. HLA-II matched adherent cells were used as APC and were incubated
with antigen overnight. The T cells were added followed by incubation for three days. 3H thymidine was added for the last 20 hours. Each
concentration of antigen was tested in duplicates. Most T-cell clones showed some degree of cross-reactivity to mycobacterial antigens. A) Depiction
of results of one clone (TCC909.A.8.2.7) which responded to MAP, MAA and M. intracellulare B) Depiction of results of one clone (TCC946.A8.2b.5)
which responded only to MAP and MAA. The data are representative for three independent experiments.
doi:10.1371/journal.pone.0005641.g003
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Figure 4. HLA restriction of T-cell clones. A) Patient CD-46, B) Patient CD-6 and C) Patient CD-9. The individual patients HLA DR/DQ serotype of
the clone donor is given in brackets after the clone identification tag. Adherent cells from HLAII DR/DQ haplotype matched donors were used as APC
and incubated with antigen overnight. T cells were added followed by further incubation for three days with addition of 3H thymidine for the last
20 hours. Left panel depicts responses using different APC. Right panel depicts blocking of the responses by addition of monoclonal antibodies
specific for either HLA-DR, HLA-DQ or HLA-DP two hours prior to addition of the T cells. The blocking assay was done in triplicates and repeated three
times. Error bars indicate mean6SD.
doi:10.1371/journal.pone.0005641.g004
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Figure 5. Epitope mapping of a MAP1508 specific T-cell clone. A) HLA-II restriction of TCC911.A.8.4.13. Left; blocking of responses by HLA
class II specific monoclonal antibodies. Right; HLA-DQ matched EBV cells were used as APC to identify HLA restriction. The patient was DQB1*0609
and DQB1*0301. Error bars indicate mean6SD. B) Proliferation of the T-cell clone in response to overlapping peptides (10 mM) of the MAP1508
protein. Left; peptides of 20 aa with10 aa overlap. Right; peptides of 15 aa overlapping with one aa ranging from position 56 to 95. The sequences are
shown.
doi:10.1371/journal.pone.0005641.g005
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on the specificity of these intestinal T cells. Duchmann et al
published two studies that showed the presence of T cells
responding to commensal bacteria in equal frequencies in UC
and CD patients with active disease [17,18], which is in agreement
with our findings. Interestingly, we found that intestinal T cells
from CD patients responded more vigorously to MAP antigens
compared with T cells from UC patients. There was also an
apparently higher frequency of MAP reactive T cells compared
with T cells responding to commensal bacteria in the CD
patients while no such difference was found in UC patients.
MAP causes a disease in ruminants with similarities to CD and
the bacterium has been found in higher frequencies in CD
patients compared to controls [14,15]. However, convincing
data showing a cellular immune response to MAP are lacking.
Some studies have looked into T cell responses against
mycobacteria in CD patients, however the methodology in the
current work is vastly different. Previous studies have largely
used PBMC and/or looked at antigen induced suppression
[24,25]. To the best of our knowledge this is the first study
where isolated intestinal T cells were used to investigate cellular
immune responses to MAP in CD patients.
All the T-cell clones in the present study produced IL-17 and/
or IFN-c. T cells that produced the inflammatory cytokines IFN-
c and IL-17 have been shown to be increased in the intestine of
CD patients [16], but the specificity of any of these Th1/Th17
clones has not previously been identified. The genetic associa-
tions of NOD2 and IL23R with CD suggest that IL-17 is relevant
for disease development. It has been shown that IL-23 induced
IL-17 production from memory T cells [26] and that stimulation
of NOD2 promoted IL-17 production through a synergistic
effect of IL-23 and IL-1 [27] . The ligand for NOD2 is known to
be muramyl dipeptide (MDP) which is present in the cell wall of
bacteria. However, it is recognized that most bacterial species
produce only N-acetyl-MDP, in contrast to mycobacteria which
also produce N-glycolyl MDP [28,29]. Studies comparing these
forms of MDP have shown that N-glycolyl MDP is more potent
than N-acetyl MDP at inducing NOD2-dependent pro-inflam-
matory responses (Behr, personal communication). Furthermore
an association between NOD2 polymorphism and resistance to
MAP in cattle has been described [30]. Altogether these recent
studies suggest a link between mycobacteria, NOD2 and the IL-
23/IL-17 pathway and are in agreement with our findings. It
cannot be excluded that the method used to isolate the T-cell
clones influenced their cytokine profile, and a future challenge is
to confirm that the MAP reactive T cells also produce IL-17 in
vivo.
In the present study there was a strong T-cell response to
MAP in the CD group, but some of the control patients also
showed some reactivity. This was not surprising considering that
a crude mycobacterial antigen preparation was used. Mycobac-
teria contain several antigens with high degree of homology, and
humans can be exposed to a range of environmental
mycobacteria that might trigger an immune response. In
addition, the Norwegian population is vaccinated with Bacille
Calmette Guerin (BCG) and one could speculate that BCG
reactive T cells can be found at the site of inflammation in IBD
patients. Although this cannot be totally excluded, it is not likely
to be a major confounding factor. The majority (69%) of the T-
cell clones did not respond to M. tuberculosis. BCG is attenuated
from Mycobacterium bovis by deletion of several genetic regions,
and all of the genes in this vaccine strain are also present in M.
tuberculosis [31,32]. Consequently, BCG reactive T cells are likely
to cross-react with antigens from M. tuberculosis. To find
conclusive evidence that the responses were caused by MAP is
difficult since proteins from MAP and MAA have a extremely
high degree of identity [23]. However, we isolated one T-cell
clone that responded only to MAP and MAA, while another
clone from another patient responded to MAA, MAP and M.
intracellulare. MAP and MAA are both subspecies of M. avium
while M. intracellulare is the mycobacterial species that is
phylogenetically closest to M. avium. Of these bacteria, MAP is
the only organism that has a predilection for the intestinal
mucosa while MAA and M. intracellulare usually causes cervical
lymphadenitis in children or also disseminated or pulmonary
disease particularly in immunocompromised individuals. These
findings suggest that at least in two of the patients the responses
were triggered by MAP or a closely related bacterium belonging
to the M. avium complex.
A future challenge is to identify how many, and which
patients have a MAP or an M. avium complex specific T-cell
response. T-cell cloning is tedious and not an option for
screening of large number of patients. An alternative is to use
MAP specific epitopes and test for recognition of these in
polyclonal T cell lines derived from intestinal biopsies of patients
carrying the relevant HLA class II restriction element.
Identification of such epitopes is challenging, but may be
achieved using a panel of MAP specific T-cell clones to screen
peptide libraries or MAP expression libraries. These methods
have previously been used successfully to identify the epitopes of
T cells of unknown specificity [33–35]. To date we have
identified the specificity of one T-cell clone. The epitope was
located on an esx protein which belongs to the highly
immunogenic ESAT family [36]. The epitope was conserved
in several pathogenic mycobacterial species, but not found in the
genome of the saprophytic M. smegmatis. Further studies will
focus on identification of MAP specific epitopes that can be used
to screen T-cell lines from a larger number of CD patients and
controls
CD presents with a variety of clinical manifestation and genes
associated with CD differs between populations. It is thus possible
that certain bacteria can be of importance in a subgroup of
patients.We believe that the isolation of tissue derived T cell clones
followed by characterization of their specificity can give novel
answers about the bacteria involved in the inappropriate
inflammatory response seen in CD. This study demonstrated the
presence of MAP reactive intestinal T-cell clones producing IFN-c
and IL-17 suggesting that they may contribute to the intestinal
inflammation.
Supporting Information
Table S1 Recombinant antigens and pooled peptides used in the
present study
Found at: doi:10.1371/journal.pone.0005641.s001 (0.06 MB
DOC)
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